Medivir AB: An All-Oral Phase IIa Study Combining Simeprevir, TMC647055 And JNJ56914845 In Hepatitis C Patients To Be Initiated

Published: Dec 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.

Help employers find you! Check out all the jobs and post your resume.

Back to news